26 research outputs found
Forward Flight Rotor Performance at Martian Atmospheric Densities and Sensitivity to Low Reynolds Numbers
Much effort has been made to enhance exploration on Mars. In addition to a rover and Mars-orbiting satellites, a Mars Helicopter Technology Demonstrator was proposed by the NASA Jet Propulsion Laboratory (JPL) to augment planetary research for the Mars 2020 Mission. Understanding rotor performance is vital for operations at Martian atmospheric conditions. The work presented is a study investigating rotor performance at Martian atmospheric conditions. Forward flight rotor tests were conducted in the Planetary Aeolian Laboratory (PAL) at NASA Ames Research Center, which has the capability to evacuate the air in the chamber to reach Martian atmospheric densities. A 1-meter-diameter rotor, roughly approximating the Mars Helicopter Technology Demonstrator, was tested at multiple atmospheric densities, including that of Mars. Rotor rotational speed, thrust, torque, power, and airspeed measurements were collected during the test. These results were then correlated with simulated cases using a mid-fidelity computational fluid dynamics software, Rotorcraft CFD (RotCFD). C81Generator (C81Gen) was used to generate airfoil aerodynamic coefficient for the spanwise locations along the rotor. To observe the differences between the C81Gen flow type modes at low Reynolds number, the simulations at Martian atmospheric densities were run under the fully turbulent, and the fully laminar flow type. In addition, Reynolds number effects (within 2x104 to 9x104) on experimental thrust coefficient, power coefficient, and figure of merit were analyzed. Within this chord- based Reynolds number range, CT and FM decreased around 26% and 36%, respectively, while CP remained fairly constant, exhibiting variations of no more than 5.5%. Despite the challenges involved in testing at a large difference of atmospheric ensities between Earth and Mars, repeatable data was obtained in all the measurements at Martian atmospheric conditions
Rotor CFD Analysis at Terrestrial and Martian Atmospheric Densities
Much effort has been made to enhance exploration on Mars. In addition to a rover and Mars-orbiting satellites, a Mars helicopter (MH) was proposed in order to augment planetary research. Computational Fluid Dynamics (CFD) simulations have been performed to have a better understanding of the behavior and performance of vertical lift Planetary Aerial Vehicles (PAV). Due to the large differences in atmospheric conditions between Mars and Earth, predicting and testing rotorcraft performance is a complex task. The goal of this project is to understand the capability of the mid-fidelity CFD software RotCFD to predict rotor performance in terms of thrust at 1013.25 milibar and 14 milibar corresponding to Terrestrial and Martian conditions, respectively. Also, in order to characterize the wind tunnel wall effects free field and wind tunnel simulations were performed, analyzed and compared. Different analytical tools have been used in order to aid with the design process for the future vertical lift planetary aerial vehicles. One of them includes experimental tests performed on a rotor in the Aeolian Wind Tunnel (AWT) facility at NASA Ames Research Center under different pressure conditions ranging from Terrestrial to Martian atmospheric conditions. Other software was used as well in order to capture the aerodynamic coefficients of the corresponding rotor sections based on the Mach and Reynolds numbers used for the experimental tests. The aerodynamic coefficients were input into RotCFD, and various simulations were performed under Terrestrial and Martian conditions in order to mimic the experimental test. Then, the obtained results from RotCFD were compared with the AWT collected data
Parental Factors Associated With the Decision to Participate in a Neonatal Clinical Trial
Importance: It remains poorly understood how parents decide whether to enroll a child in a neonatal clinical trial. This is particularly true for parents from racial or ethnic minority populations. Understanding factors associated with enrollment decisions may improve recruitment processes for families, increase enrollment rates, and decrease disparities in research participation.
Objective: To assess differences in parental factors between parents who enrolled their infant and those who declined enrollment for a neonatal randomized clinical trial.
Design, setting, and participants: This survey study conducted from July 2017 to October 2019 in 12 US level 3 and 4 neonatal intensive care units included parents of infants who enrolled in the High-dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) trial or who were eligible but declined enrollment. Data were analyzed October 2019 through July 2020.
Exposure: Parental choice of enrollment in neonatal clinical trial.
Main outcomes and measures: Percentages and odds ratios (ORs) of parent participation as categorized by demographic characteristics, self-assessment of child's medical condition, study comprehension, and trust in medical researchers. Survey questions were based on the hypothesis that parents who enrolled their infant in HEAL differ from those who declined enrollment across 4 categories: (1) infant characteristics and parental demographic characteristics, (2) perception of infant's illness, (3) study comprehension, and (4) trust in clinicians and researchers.
Results: Of a total 387 eligible parents, 269 (69.5%) completed the survey and were included in analysis. This included 183 of 242 (75.6%) of HEAL-enrolled and 86 of 145 (59.3%) of HEAL-declined parents. Parents who enrolled their infant had lower rates of Medicaid participation (74 [41.1%] vs 47 [55.3%]; P = .04) and higher rates of annual income greater than $55 000 (94 [52.8%] vs 30 [37.5%]; P = .03) compared with those who declined. Black parents had lower enrollment rates compared with White parents (OR, 0.35; 95% CI, 0.17-0.73). Parents who reported their infant's medical condition as more serious had higher enrollment rates (OR, 5.7; 95% CI, 2.0-16.3). Parents who enrolled their infant reported higher trust in medical researchers compared with parents who declined (mean [SD] difference, 5.3 [0.3-10.3]). There was no association between study comprehension and enrollment.
Conclusions and relevance: In this study, the following factors were associated with neonatal clinical trial enrollment: demographic characteristics (ie, race/ethnicity, Medicaid status, and reported income), perception of illness, and trust in medical researchers. Future work to confirm these findings and explore the reasons behind them may lead to strategies for better engaging underrepresented groups in neonatal clinical research to reduce enrollment disparities
Finishing the euchromatic sequence of the human genome
The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead
Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19
IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19.
Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19.
DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022).
INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days.
MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes.
RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively).
CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570
Experimental Forward Flight Rotor Performance Testing from Terrestrial to Martian Atmospheric Densities
With the recent interest in Martian exploration using Unmanned Aerial Vehicles (UAV), an experimental study was conducted to investigate rotor performance at Martian atmospheric conditions. Both simulation and testing of rotors is vital for the evaluation of performance and behavior of rotor, especially for operations at Martian atmospheric densities and pressures. Testing and measuring rotor forward flight performance at Martian atmospheric conditions is a relatively unexplored area. Therefore, an experimental study was performed in a wind tunnel to investigate helicopter forward flight performance and to demonstrate successful rotor operation at Martian atmospheric densities. This work was a continuation of the first ever wind tunnel test of a simulated rotorcraft in forward flight at Martian atmospheric densities. A test was conducted in a facility, which could be evacuated to the atmospheric pressure and density of Mars. A 40-in diameter rotor, roughly approximating the scale of the proposed Mars Helicopter design by the NASA Jet Propulsion Laboratory (JPL), was tested in forward flight at Mars atmospheric pressure at the NASA Ames Planetary Aeolian Laboratory (PAL). In this forward flight testing, the drive system of the Martian Surface Wind Tunnel (MARSWIT) was never turned on. The goal of this experiment was to collect rotor thrust, rotational speed, power, torque, and wind speed measurements. Subsequently, these results can be used for correlation with simulated cases using a mid-fidelity Computational Fluid Dynamics (CFD) simulation. Rotor thrust and power seem to decrease approximately proportional to the decrease in density. However, the Reynolds number has an effect on rotor performance that might also be contributing to the change in thrust and power. This effect plays a vital role in rotor performance at reduced pressure that cannot be neglected in the simulation. Despite the challenges involved in testing at a large difference of atmospheric densities between Earth and Mars, repeatable data is obtained in all the measurements at Martian atmospheric conditions
Parental Enrollment Decision-Making for a Neonatal Clinical Trial.
OBJECTIVE: To describe the parental experience of recruitment and assess differences between parents who participated and those who declined to enroll in a neonatal clinical trial. STUDY DESIGN: Survey conducted at 12 US NICUs of parents of infants who enrolled in the High dose Erythropoietin for Asphyxia and encephaLopathy (HEAL) trial or who were eligible but declined enrollment. Questions assessed six factors of the parental experience of recruitment: 1) interactions with research staff; 2) the consent experience; 3) perceptions of the study; 4) decisional conflict; 5) reasons for/against participation; and 6) timing of making the enrollment decision. RESULTS: 269 of 387 eligible parents, including 183 of 242 (75.6%) of HEAL enrolled and 86 of 145 (59.3%) of HEAL declined parents were included in analysis. Parents who declined to enroll more preferred to be approached by clinical team members rather than by research team members (72.9% vs. 49.2%, p-value = 0.005). Enrolled parents more frequently reported positive initial impressions (54.9% vs. 10.5%, p-value <0.001). Many parents in both groups made their decision early in the recruitment process. Considerations of reasons for/against participation differed by enrollment status. CONCLUSIONS: Understanding how parents experience recruitment, and how this differs by enrollment status, may help researchers improve recruitment processes for families and increase enrollment. The parental experience of recruitment varied by enrollment status. These findings can guide future work aiming to inform optimal recruitment strategies for neonatal clinical trials
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
© 2020 Elsevier Ltd. All rights reserved.Background: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Methods: This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0·3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analyses included all patients who received one or more dose of patisiran up to the data cutoff. This study is registered with ClinicalTrials.gov, NCT02510261.
Findings: Between July 13, 2015, and Aug 21, 2017, of 212 eligible patients, 211 were enrolled: 137 patients from the APOLLO-patisiran group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE patisiran group. At the data cutoff on Sept 24, 2018, 126 (92%) of 137 patients from the APOLLO-patisiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE patisiran group had completed 12-month assessments. At 12 months, improvements in mNIS+7 with patisiran were sustained from parent study baseline with treatment in the global OLE (APOLLO-patisiran mean change -4·0, 95 % CI -7·7 to -0·3; phase 2 OLE patisiran -4·7, -11·9 to 2·4). Mean mNIS+7 score improved from global OLE enrolment in the APOLLO-placebo group (mean change from global OLE enrolment -1·4, 95% CI -6·2 to 3·5). Overall, 204 (97%) of 211 patients reported adverse events, 82 (39%) reported serious adverse events, and there were 23 (11%) deaths. Serious adverse events were more frequent in the APOLLO-placebo group (28 [57%] of 49) than in the APOLLO-patisiran (48 [35%] of 137) or phase 2 OLE patisiran (six [24%] of 25) groups. The most common treatment-related adverse event was mild or moderate infusion-related reactions. The frequency of deaths in the global OLE was higher in the APOLLO-placebo group (13 [27%] of 49), who had a higher disease burden than the APOLLO-patisiran (ten [7%] of 137) and phase 2 OLE patisiran (0 of 25) groups.
Interpretation: In this interim 12-month analysis of the ongoing global OLE study, patisiran appeared to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Continued long-term follow-up will be important for the overall assessment of safety and efficacy with patisiran.info:eu-repo/semantics/publishedVersio
Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries
Background:
Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0–14 years) and adults (aged 15–99 years) diagnosed with a haematological malignancy during 2000–14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0–24 years).
Methods:
We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0–14 years), adolescents (15–19 years), and young adults (20–24 years). We categorised leukaemia subtypes according to the International Classification of Childhood Cancer (ICCC-3), updated with International Classification of Diseases for Oncology, third edition (ICD-O-3) codes. We estimated 5-year net survival by age and morphology, with 95% CIs, using the non-parametric Pohar-Perme estimator. To control for background mortality, we used life tables by country or region, single year of age, single calendar year and sex, and, where possible, by race or ethnicity. All-age survival estimates were standardised to the marginal distribution of young people with leukaemia included in the analysis.
Findings:
164 563 young people were included in this analysis: 121 328 (73·7%) children, 22 963 (14·0%) adolescents, and 20 272 (12·3%) young adults. In 2010–14, the most common subtypes were lymphoid leukaemia (28 205 [68·2%] patients) and acute myeloid leukaemia (7863 [19·0%] patients). Age-standardised 5-year net survival in children, adolescents, and young adults for all leukaemias combined during 2010–14 varied widely, ranging from 46% in Mexico to more than 85% in Canada, Cyprus, Belgium, Denmark, Finland, and Australia. Individuals with lymphoid leukaemia had better age-standardised survival (from 43% in Ecuador to ≥80% in parts of Europe, North America, Oceania, and Asia) than those with acute myeloid leukaemia (from 32% in Peru to ≥70% in most high-income countries in Europe, North America, and Oceania). Throughout 2000–14, survival from all leukaemias combined remained consistently higher for children than adolescents and young adults, and minimal improvement was seen for adolescents and young adults in most countries.
Interpretation:
This study offers the first worldwide picture of population-based survival from leukaemia in children, adolescents, and young adults. Adolescents and young adults diagnosed with leukaemia continue to have lower survival than children. Trends in survival from leukaemia for adolescents and young adults are important indicators of the quality of cancer management in this age group